| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/28/2010 | WO2010010949A1 Lipase inhibitor |
| 01/28/2010 | WO2010010935A1 Optically active heterocyclidene-n-arylacetamide derivative |
| 01/28/2010 | WO2010010934A1 Heterocyclidene derivative having p-substituted arylacetamide |
| 01/28/2010 | WO2010010933A1 Heterocyclidene-n-(3,4-dihydro-2(1h)-quinazolin-5-yl) acetamide derivative |
| 01/28/2010 | WO2010010909A1 Therapeutic agent for chronic renal failure |
| 01/28/2010 | WO2010010797A1 Pharmaceutical composition comprising dyrk-inhibiting compound |
| 01/28/2010 | WO2010010786A1 Enhancer of expression of β3-adrenergic receptor |
| 01/28/2010 | WO2010010702A1 Prophylactic or therapeutic agent for axial myopia |
| 01/28/2010 | WO2010010079A1 Diagnostic agents selective against metalloproteases |
| 01/28/2010 | WO2010009667A1 Method for producing an extract of vitis vinifera having high orac values and the extract produced by said method |
| 01/28/2010 | WO2009118753A3 Process for preparation of naratriptan hydrochloride |
| 01/28/2010 | WO2009024977A3 Saccharide-containing protein conjugates and uses thereof |
| 01/28/2010 | US20100022657 Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine |
| 01/28/2010 | US20100022651 Method For Increasing Hair Growth |
| 01/28/2010 | US20100022643 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| 01/28/2010 | US20100022594 thiophene sulfonamide derivatives such as 5-Chloro-N-[(S)-2-hydroxy-1-phenylethyl]thiophene-2-sulfonamide, that inhibit the production of beta amyloid protein from amyloid precursor protein; capable of passing through the blood-brain barrier, used for treatment of Alzheimer's disease and Down's syndrome |
| 01/28/2010 | US20100022577 Dry syrup containing loratadine |
| 01/28/2010 | US20100022558 Treatment of insomnia |
| 01/28/2010 | US20100022551 Trimetazidine for use in the treatment of fibromyalgia syndrome and related conditions |
| 01/28/2010 | US20100022542 Compounds exhibiting thrombopoietin receptor agonism |
| 01/28/2010 | US20100022501 such as drinabant (N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide) with an excipient selected from Polysorbate 80 or PEG hydroxystearate; drinkable dosage forms |
| 01/28/2010 | US20100022490 Zilpaterol Enantiomer Compositions and Methods of Making and Using Such Compositions |
| 01/28/2010 | US20100022449 Receptor-avid exogenous optical contrast and therapeutic agents |
| 01/28/2010 | US20100021553 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof |
| 01/28/2010 | US20100021520 Biomaterial implants |
| 01/28/2010 | US20100021507 Method and Composition for Making an Orally Disintegrating Dosage Form |
| 01/28/2010 | US20100021482 Novel death associated proteins, and thap1 and par4 pathways in apoptosis control |
| 01/28/2010 | US20100021469 Functional role of adrenomedullin (am) and the gene related product (pamp) in human pathology and physiology |
| 01/28/2010 | US20100021467 Method of detecting a cancer cell by aberrant expression of a human k+ ion channel |
| 01/28/2010 | US20100021442 Method for promoting immunotherapy using an agent for elevating dendritic cell precursor level in blood |
| 01/28/2010 | US20100021439 Methods and compositions for treating intervertebral disc degeneration |
| 01/28/2010 | US20100021430 Horse feed and treatment methods |
| 01/28/2010 | US20100021389 Radiographic contrast agent for postmortem, experimental and diagnostic angiography |
| 01/27/2010 | EP2147922A1 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| 01/27/2010 | EP2147914A1 Aminodihydrothiazine derivatives substituted with cyclic groups |
| 01/27/2010 | EP2147684A1 Diagnostic Agents Selective Against Metalloproteases |
| 01/27/2010 | EP2147681A1 Compositions and methods for treating lysosomal storage disease |
| 01/27/2010 | EP2147679A2 Compositions and methods for modulating blood-brain barrier transport |
| 01/27/2010 | EP2147675A1 Agent for stimulating lymphatic drainage |
| 01/27/2010 | EP2147672A1 Cytotoxic t cell activator comprising ep4 agonist |
| 01/27/2010 | EP2147042A1 Dendritic molecules |
| 01/27/2010 | EP1554286B1 Fused heterocyclic isoxazoline derivatives and their use as anti-depressants |
| 01/27/2010 | EP1438298B1 Piperazine derivatives with ccr1 receptor antagonist activity |
| 01/27/2010 | EP1343485B1 Drug delivery system comprising a lipid-based nitric oxide donor |
| 01/27/2010 | CN101633650A Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 01/27/2010 | CN101633646A Salts of valsartan |
| 01/27/2010 | CN101633645A N3 alkylated benzimidazole derivatives as mek inhibitors |
| 01/27/2010 | CN101633644A N3 alkylated benzimidazole derivatives as mek inhibitors |
| 01/27/2010 | CN101633636A Peptidomimetic protease inhibitors |
| 01/27/2010 | CN101632676A Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/27/2010 | CN101632669A Method of using diketopiperazines and composition containing them |
| 01/27/2010 | CN101632663A Novel molecular target for neurotoxicity |
| 01/27/2010 | CN100584842C Thiazole derivative |
| 01/27/2010 | CN100584819C Substituted 4-aminocyclohexanol derivatives |
| 01/27/2010 | CN100584383C Pharmaceutical composition with Meclofenoxate hydrochloride capable of preventing hydrolysis |
| 01/27/2010 | CN100584380C Production of gamma immune protein capsules |
| 01/27/2010 | CN100584336C Medicinal compositions |
| 01/27/2010 | CN100584324C Use of camostat in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) |
| 01/26/2010 | US7653495 Comprises series of steps including identifying cavity proximal to functional critical site, determining physical parameters of cavity, identifying functional groups which can be accommodated by cavity, testing compounds comprising such functional groups in an in vitro assay to determine which are active |
| 01/26/2010 | US7652155 Diamine derivative, production process therefor and antioxidant |
| 01/26/2010 | US7652144 Compounds as PDE IV and TNF inhibitors |
| 01/26/2010 | US7652141 Immunosuppressants, analgesics, antiinflammatory agents |
| 01/26/2010 | US7652060 Small molecule rotamase enzyme inhibitors |
| 01/26/2010 | US7652054 Gastrointestinal disorders; cardiovascular disorders; dyspepsia;anticancer agents; antiulcer agents |
| 01/26/2010 | US7652045 Activator of peroxisome proliferator-activated receptor δ |
| 01/26/2010 | US7652038 Methods of reducing angiogenesis |
| 01/26/2010 | US7652022 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; |
| 01/26/2010 | US7652019 5,6-trimethylenepyrimidin-4-one compounds |
| 01/26/2010 | US7652017 Therapy for central nervous system, brain disorders |
| 01/26/2010 | US7652012 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide maleate and pharmaceutical compositions thereof |
| 01/26/2010 | US7651999 2′, 5′-oligoadenylate analogs |
| 01/26/2010 | US7651997 Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them |
| 01/26/2010 | US7651844 Method for screening agents capable of treating obesity |
| 01/26/2010 | US7651692 Skin disorders; cosmetics; aging resistance |
| 01/26/2010 | US7651678 Methods to impair hematologic cancer progenitor cells and compounds related thereto |
| 01/26/2010 | CA2481012C Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| 01/26/2010 | CA2469380C Heteroaryl-substituted aminocyclohexane derivatives |
| 01/26/2010 | CA2465206C Polymeric thiol-linked prodrugs |
| 01/26/2010 | CA2447099C Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/26/2010 | CA2430579C Isoindolin-1-one glucokinase activators |
| 01/26/2010 | CA2422889C Method for the treatment of neurological and neuropsychological disorders |
| 01/26/2010 | CA2408710C Compositions and methods for the treatment of colorectal cancer |
| 01/26/2010 | CA2394188C Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/26/2010 | CA2390263C Method for producing metabolites from plants cultivated in soil-less medium |
| 01/26/2010 | CA2349629C Methods for the production of tcr gamma delta t cells |
| 01/26/2010 | CA2346084C Benzothieno[3,2-c]pyridines as .alpha.2 antagonists |
| 01/26/2010 | CA2319255C Pharmaceuticals comprising n,n'-bis(2- hydroxybenzyl) ethylenediamine-n, n'-diacetic acid for iron chelating therapy |
| 01/26/2010 | CA2303934C Tetrazole-containing rapamycin analogs with shortened half-lives |
| 01/26/2010 | CA2275345C Pro-drugs and counterparts of camptothecin, their application as medicines |
| 01/26/2010 | CA2230086C Method to improve the biological and antiviral activity of protease inhibitors |
| 01/26/2010 | CA2222524C Somatostatin peptides |
| 01/26/2010 | CA2213500C Use of g class immunoglobulins for the topical treatment of atopic dermatitis |
| 01/21/2010 | WO2010008519A2 In vitro diagnostic markers comprising carbon nanoparticles and kits |
| 01/21/2010 | WO2010008317A1 Agent for activating stem cells |
| 01/21/2010 | WO2010007972A1 Novel indole derivative having carbamoyl group, ureide group and substituted oxy group |
| 01/21/2010 | WO2010007966A1 Azole compound |
| 01/21/2010 | WO2010007944A1 Nitrogenated bicyclic heterocyclic compound |
| 01/21/2010 | WO2010007943A1 Nitrogenated heterocyclic compound |
| 01/21/2010 | WO2010007800A1 Novel uracil compound having amide structure and salt thereof |
| 01/21/2010 | WO2010007788A1 Glycyrrhetinic acid derivative and use thereof |